Wall Street spent Monday in a tug of war: the Dow rose while the Nasdaq and the small-cap Russell 2000 fell, memory-chip stocks slid, and oil climbed toward $93. With JPMorgan, Goldman Sachs and other big banks reporting Tuesday morning, here are 10 stocks under $5 to watch tomorrow. The list leans toward smaller, lesser-known names that recently caught attention, from an offshore California oil producer to a $22 million insulin-pump maker, and none of them appeared in our recent watchlists.
Stocks Under $5 to Watch Tomorrow: Monday’s Market Snapshot
| Metric | Monday Close / Reading |
|---|---|
| Dow Jones Industrial Average | 51,850.55 (+0.38%) |
| S&P 500 | 7,807.24 (-0.06%) |
| Nasdaq Composite | 27,245.90 (-0.44%) |
| Russell 2000 | 2,794.48 (-0.45%) |
| 10-Year Treasury Yield | ~5.24% |
| VIX | ~15.2 |
| WTI Crude (Nov. futures) | $93.22 (+1.5%) |
| Gold / Bitcoin | ~$4,195 / ~$81,700 |
The Dow rose 0.38% while the Nasdaq and Russell slipped, with semiconductors down about 2.7%, and memory stocks weighed on the Nasdaq. Energy led the S&P 500 as oil rose again. Goldman Sachs reports Tuesday alongside JPMorgan, Wells Fargo, Citigroup, UnitedHealth and Johnson & Johnson, and September CPI arrives Wednesday with a 3.6% annual reading expected.
Data note: Closes are Monday, October 12 figures where we could verify them. Where a stock’s latest quote was not confirmed, the table says “last verified” with the date, and you should check the live price before acting. RSI and MACD are omitted where feeds were stale. Support and resistance levels are analytical zones built from verified closes, 52-week extremes, offering prices and round numbers, not guaranteed targets. These are speculative, low-priced stocks, several with micro-cap market values.
1. Sable Offshore (SOC) | Close $3.73 (+0.3%) | California Oil Pennies Meet a JPMorgan $10 Target
Platform Hondo Restart, a Dilutive Raise and a Street-High Target 170% Away
JPMorgan initiated Sable at Overweight with a $10 target on October 2, roughly 178% above the price at the time.
| Metric | Value |
|---|---|
| Last Close | $3.73 (+0.27%) |
| 52-Week Range | $2.88 – roughly $25+ (high not consistently reported) |
| Market Cap | ~$0.7B (estimated from ~187M shares after the raise) |
| P/E / Dividend | Negative / None |
| Volume vs. Average | Average ~9.3M shares; Monday’s final tally not confirmed |
| Analyst View | JPMorgan Overweight $10; Jefferies Buy $9 (cut from $11) |
| Offering Price | 32.5M shares at $3.08 plus $300M of convertible notes |
| Support 1 / 2 / 3 | $3.59 / $3.08 / $2.88 |
| Resistance 1 / 2 / 3 | $4.00 / $4.50 / $5.00 |
Catalyst & Latest News: Sable reported its first profitable quarter, and it is bringing more wells online and preparing the Platform Hondo restart, with a Q4 restart targeted. With WTI at $93, producers are in focus.
Technicals: The stock sits just above the $3.08 offering price after a drop of more than 40% when the $1.2 billion financing plan surfaced. Per Stock Analysis, the 52-week low is $2.88.
Fundamentals: The Santa Ynez Unit already generates revenue, and the new equity and convertible notes were meant to rework an Exxon loan. Reports said JPMorgan saw limited demand for the loan despite a 15% rate.
Bull Case: A Hondo restart, $90+ oil and targets between $9 and $15. Bear Case: Dilution, a heavy debt load and California regulatory and pipeline risk.
What to Watch:
- Any Hondo restart date
- A hold of $3.59
- Oil’s reaction to Middle East headlines
Forecast: Holding $3.59 keeps a base above the offering price, with $4 first resistance. A break under $3.08 retests the $2.88 low.
Why This Matters: SOC is a leveraged bet on both oil and a single California restart.
2. Gogo (GOGO) | Close $2.54 (+9.3%) | Satellite Connectivity Stock Jumps With No Headline
A 9% Pop From Lows Last Seen in Early October, and Nobody Has Said Why
Gogo rose 9.26% to $2.54 on Monday per Benzinga’s small-cap movers list, and we could not verify a company-specific trigger.
| Metric | Value |
|---|---|
| Last Close | $2.54 (+9.26%); prior close ~$2.32 |
| Recent Closes | Oct 8: $2.26; Oct 6: $2.30; Oct 5: $2.14 |
| 52-Week Range | Not confirmed; traded near $4.18 on July 31 |
| Market Cap | ~$345M (about 136M shares) |
| P/E / Dividend | Not confirmed / None |
| Volume vs. Average | Average ~1.75M shares; Monday’s final tally not confirmed |
| YTD | About -45% as of mid-September |
| Support 1 / 2 / 3 | $2.32 / $2.22 / $2.11 |
| Resistance 1 / 2 / 3 | $2.55 / $2.83 / $3.19 |
Catalyst & Latest News: Shares fell 12% on August 10 after earnings and have drifted from about $4 at the end of July to the low $2s.
Technicals: The Monday close lands almost exactly on the $2.52–$2.55 area from mid-September, so that zone is the first test.
Fundamentals: Gogo was down roughly 45% for the year in mid-September, with one analyst upgrade in the prior month.
Bull Case: A heavily sold stock bouncing on higher volume. Bear Case: An unexplained spike can fade, and the stock is still about 40% below its July level.
What to Watch:
- Whether $2.55 breaks
- A hold of the $2.32 gap
- Any company statement explaining the move
Forecast: A close above $2.55 targets $2.83. A fade below $2.32 returns the stock to the $2.11–$2.26 range.
Why This Matters: Gogo shows how a quiet small cap can jump on flows alone, and the next move depends on whether news follows.
3. LG Display (LPL) | Close $2.75 | Fresh 52-Week Low for the OLED Maker
The Apple-Supplier ADR Slips Under Its 52-Week Low as the Q3 Report Approaches
LG Display’s ADR closed near $2.75, just under a 52-week low of $2.76.
| Metric | Value |
|---|---|
| Last Close | ~$2.75 |
| 52-Week Range | $2.76 – $5.83 (low just broken) |
| Market Cap | ~$2.8B (estimated; $3.3B at $3.30 in September) |
| P/E / Dividend | Negative (EPS about -$0.99) / None |
| Volume vs. Average | Average ~2.9M shares; Monday’s final tally not confirmed |
| Analyst View | Hold; 12-month target ~$4.30 |
| Next Earnings | November 5 |
| Support 1 / 2 / 3 | $2.75 / $2.50 / $2.25 |
| Resistance 1 / 2 / 3 | $2.90 / $3.30 / $3.71 |
Catalyst & Latest News: Q2 showed a narrowing operating loss and a profit for the first half, with positive shipment and pricing commentary for Q3. Apple’s 2026 OLED lineup reportedly relies on Samsung and LG.
Technicals: The stock has broken to a new low in a market where memory and semiconductor stocks sold off Monday.
Fundamentals: The company is described as heavily indebted after exiting large-panel LCD, and it trails Samsung Display in Apple panel volumes.
Bull Case: A Q3 outlook with higher OLED mix, auto and IT display growth, and a stock at a 52-week low. Bear Case: Losses, debt, and strong competition from Samsung Display.
What to Watch:
- A hold of $2.75
- A reclaim of $2.90
- Any Q3 preview or guidance from Korea
Forecast: Reclaiming $2.90 would take the stock back inside its 52-week range. Failing that, $2.50 is the next reference.
Why This Matters: LPL is a distressed hardware turnaround where the chart, not the story, is currently in charge.
4. Modular Medical (MODD) | Price $2.68 | A $22 Million Insulin-Pump Maker Starts Its Launch
Pivot Patch Pump Rolls Into Five U.S. Markets This Month
Modular Medical said it would begin the first phase of the Pivot launch in five U.S. markets in October 2026.
| Metric | Value |
|---|---|
| Last Price | $2.68 (Oct 12); Sept 10 close $2.64 |
| 52-Week Range | $1.72 – $30.00 (split-adjusted) |
| Market Cap | ~$22M |
| P/E / Dividend | Negative (EPS about -$9.85) / None |
| Volume vs. Average | Average ~289K shares |
| Analyst View | Three Buy ratings; no published targets |
| Key Stat | 1-for-30 reverse split; $3.4M registered direct offering |
| Support 1 / 2 / 3 | $2.52 / $2.48 / $1.72 |
| Resistance 1 / 2 / 3 | $2.81 / $3.61 / $4.77 |
Catalyst & Latest News: The company signed a national pharmacy benefit manager contract, and the FDA cleared software upgrades to Pivot. The first rollout markets are Atlanta, Cincinnati/Lexington, Dallas, Houston and Philadelphia.
Technicals: The stock fell 6% on September 10 to $2.64 and has held a narrow band since, with the prior close near $2.81 first resistance.
Fundamentals: The stock traded at $4.77 in June and about $5 in July before sliding, and Yahoo lists a 52-week range of $1.72 to $30 after split adjustments. Dilution is part of the story.
Bull Case: Commercial launch, PBM access and a tiny market value. Bear Case: Heavy losses, a reverse split and repeated equity raises.
What to Watch:
- First-market sales or prescription commentary
- Any new financing
- A hold of $2.52
Forecast: Early launch data could lift MODD through $2.81 toward $3.60. A financing announcement would put $2.48 at risk.
Why This Matters: MODD is a tiny medical-device launch where one number, early uptake, will define the story.
5. Serina Therapeutics (SER) | Price $1.94 | Parkinson’s Study Advances to Cohort 2
A $29 Million Biotech With a Registrational Parkinson’s Trial and Two Buy Ratings
Serina’s safety committee cleared the SER-252 Phase 1b study to move on to Cohort 2.
| Metric | Value |
|---|---|
| Last Price | $1.94 (Oct 12) |
| 52-Week Range | $1.22 – $7.92 |
| Market Cap | ~$29M (about 15M shares) |
| P/E / Dividend | Negative (EPS about -$1.87) / None |
| Volume vs. Average | Average ~1.4M shares |
| Analyst View | HC Wainwright Buy $15; BTIG Buy $8; averages cited $9.50–$13 |
| Funding | Up to $30M private placement |
| Support 1 / 2 / 3 | $1.75 / $1.53 / $1.22 |
| Resistance 1 / 2 / 3 | $2.00 / $2.54 / $3.00 |
Catalyst & Latest News: Cohort 1 data showed a pharmacokinetic profile consistent with sustained apomorphine exposure, with some individual patients showing sustained motor improvement on exploratory measures. The CEO discussed progress in a September 24 webinar.
Technicals: The stock sits near the lower fifth of its 52-week range, per Stock Analysis, and recent closes cluster around $1.5–$2.5.
Fundamentals: Morningstar lists about 15 million shares and a market value near $27 million, and there is no revenue beyond grants.
Bull Case: Registrational Parkinson’s study, analyst targets far above the price, and a partnership with Gannet BioChem. Bear Case: Cash needs, dilution, and early data from a handful of patients.
What to Watch:
- Cohort 2 dosing updates
- A hold of $1.75
- Any financing or partnership news
Forecast: Reclaiming $2.00 points to $2.54. A loss of $1.75 retests the $1.53 area.
Why This Matters: SER shows how tiny the market value of a clinical-stage name can be relative to the size of its target market.
6. QTREX Quantum (QTEX) | Last Verified $1.77 (Oct 9) | The Quantum Cryogenics Stock That Moved 39% in a Day
A Former Ventilator Company Rebrands for Quantum Computing and Keeps Making Headlines
QTREX Quantum traded at $1.77 on October 9 with a market value near $111 million, after a 39% single-day jump earlier in the week.
| Metric | Value |
|---|---|
| Last Verified Price | $1.77 (Oct 9); a ~39% one-day move was logged earlier in October |
| 52-Week Range | $0.28 – $3.85 |
| Market Cap | ~$111M |
| P/E / Dividend | Negative / None |
| Volume vs. Average | Average ~2M shares |
| Analyst View | One cited target of $2.00 |
| Key Stat | Shelf registrations totaling $12.6M |
| Support 1 / 2 / 3 | $1.53 / $1.18 / $1.00 |
| Resistance 1 / 2 / 3 | $2.01 / $2.50 / $3.07 |
Catalyst & Latest News: The company, formerly Inspira Technologies, rebranded in May and shifted toward cryogenic chip carriers for quantum computing, and a $10 million private placement and an NYU Langone ART100 order fueled a prior 322% surge.
Technicals: The stock has ranged from about $0.91 in August to above $3 in May, so $2.01 and $1.53 are reference levels from recent sessions.
Fundamentals: The company serves aerospace, defense and advanced electronics customers alongside its medical-device roots.
Bull Case: Quantum-computing hype, defense customers and heavy retail interest. Bear Case: Shelf registrations raise dilution concerns, and the stock gave back most of its May spike.
What to Watch:
- A hold of $1.53
- Any new quantum partnership
- Offering activity
Forecast: Holding $1.53 keeps $2.01 in reach. A loss of that level puts $1.18 in play.
Why This Matters: QTEX is the sector’s reminder that a quantum label can move a stock before the revenue exists.
7. Yatsen Group (YSG) | Price $2.56 | Perfect Diary Maker Near Its 52-Week Low After a Skincare Surge
Skincare Revenue Jumps 40% While Losses Widen: The Market Wants Both Halves of the Story
Yatsen’s skincare revenue rose 40.4% in Q2, but losses widened and Q3 guidance was cautious.
| Metric | Value |
|---|---|
| Last Price | $2.56 (Oct 12); $2.53 on Sept 2 |
| 52-Week Range | $2.15 – $10.70 |
| Market Cap | ~$250M |
| P/E / Dividend | Negative (EPS about -$0.21 to -$0.33) / None |
| Volume vs. Average | Average ~130K–153K shares |
| Analyst View | JPMorgan cut its target to $3.80 from $4.70; 1-year consensus estimate ~$4.04 |
| Support 1 / 2 / 3 | $2.50 / $2.15 / $2.00 |
| Resistance 1 / 2 / 3 | $2.98 / $3.40 / $3.80 |
Catalyst & Latest News: Yatsen announced a Perfect Diary partnership with Sephora in China, part of a shift toward clinical and premium brands.
Technicals: The stock sits about 19% above its $2.15 low and roughly 76% below its high, per Yahoo Finance.
Fundamentals: Revenue grew 26.7% in 2025 with skincare leading, and the company returned to non-GAAP profitability then. Morningstar lists price-to-sales near 0.5.
Bull Case: Premium-brand mix, a Sephora channel and a price-to-sales ratio near 0.5. Bear Case: Wider losses, cautious Q3 guidance and weak China consumer demand.
What to Watch:
- A hold of $2.50
- Analyst target changes
- Q3 trends in skincare mix
Forecast: A close above $2.98 would signal a base. Losing $2.50 reopens the $2.15 low.
Why This Matters: YSG is a turnaround where revenue mix is improving faster than profit.
8. Banco Bradesco (BBD) | Last Verified $4.33 (Oct 6) | Brazil’s Election Rally Lifts a $38 Billion Bank Under $5
A Cheap-Priced Giant: Ten Straight Quarters of Better Profit Meets a Political Rally
Bradesco ADRs jumped about 19% on October 6 as Brazilian assets rallied, and recurring net income rose 16.2% in Q2.
| Metric | Value |
|---|---|
| Last Verified Price | $4.33 (Oct 6; +18.8% that day) |
| 52-Week Range | Not confirmed |
| Market Cap | ~$37.9B |
| P/E / Dividend | Not confirmed / Not confirmed |
| Volume vs. Average | ~31M shares on October 6 |
| Key Stat | Loans +11.6%; revenue +10.3% YoY |
| Support 1 / 2 / 3 | $4.00 / $3.74 / $3.50 |
| Resistance 1 / 2 / 3 | $4.50 / $5.00 / $5.50 |
Catalyst & Latest News: The bank is raising about $2 billion to fund technology and commercial investments. Brazilian stocks surged in early October, with the country’s largest banks among the week’s best performers.
Technicals: The 19% spike makes $4.00 the key level, and the preferred-share ticker BBDO traded near $3.74.
Fundamentals: Q2 marked the 10th consecutive quarter of improving recurring profit.
Bull Case: Improving profit, loan growth and a rally in Brazilian assets. Bear Case: Brazil’s economic outlook, a capital raise, and a stock that already jumped in a day.
What to Watch:
- A hold of $4.00
- Brazilian currency and bond moves
- Capital-raise details
Forecast: Holding $4.00 keeps $4.50 in view. A reversal of the election rally targets $3.74.
Why This Matters: BBD is the large-bank way to trade a Brazil rebound under $5.
9. Kosmos Energy (KOS) | Last Verified ~$2.24 | A Leveraged Oil Play Up 150% This Year
$100 Brent and Houthi Attacks Keep Offshore Producers on the Move
Kosmos was up about 150% for the year at $2.24 in a recent oil-rally session, still 32% below its May high of $3.27.
| Metric | Value |
|---|---|
| Last Verified Price | ~$2.24 (recent oil-rally session; confirm live price) |
| 52-Week High | $3.27 (May 2026) |
| YTD | About +150% |
| Market Cap / P/E | Not confirmed / Negative |
| Dividend | None |
| Volume vs. Average | Not confirmed |
| Key Stat | 72 moves above 5% in the past year |
| Support 1 / 2 / 3 | ~$2.10 / $2.00 / $1.75 |
| Resistance 1 / 2 / 3 | ~$2.50 / $3.08 / $3.27 |
Catalyst & Latest News: Brent has been near $100, with Houthi attacks and Hormuz talks driving the swings. Kosmos guided to about 15% production growth and 20% lower operating costs for 2026.
Technicals: The stock has traded as high as $3.08 and $3.27 this year, so those are the upside references.
Fundamentals: The company sold its Equatorial Guinea assets for up to $220 million and targets at least a 10% debt cut by year-end.
Bull Case: $90+ oil, production growth and cost cuts. Bear Case: High leverage, volatility, and exposure to a ceasefire that could drop oil quickly.
What to Watch:
- Oil’s reaction to Middle East headlines
- A hold of $2.00
- Debt-reduction updates
Forecast: Oil staying above $90 supports a push to $2.50. A peace headline would likely test $2.00.
Why This Matters: KOS is a high-beta way to own oil, and headlines can cut both ways.
10. Ardelyx (ARDX) | Last Verified $3.90 (Aug 20) | Heavy Put Buying and 10% Short Interest
A $970 Million Drug Seller Trades Under $4 After a Guidance Cut, With Puts Piled on the $4 Strike
Ardelyx fell about 18% to $3.98 after cutting IBSRELA guidance and pulling its XPHOZAH target.
| Metric | Value |
|---|---|
| Last Verified Close | $3.90 (Aug 20); confirm the live price |
| 52-Week Range | ~$3.90 – $7.99 (close basis) |
| Market Cap | ~$972M (about 249M shares) |
| P/E / Dividend | Negative / None |
| Volume vs. Average | Average ~4.1M shares |
| Short Interest | 26.2M shares (10.5% of float, ~11 days to cover) |
| Analyst View | 11 Buy ratings; Citi target cut to $11 from $14 |
| Q2 Revenue | $118M (+31%) |
| Support 1 / 2 / 3 | $3.90 / $3.50 / $3.16 |
| Resistance 1 / 2 / 3 | $4.00 / $4.50 / $5.00 |
Catalyst & Latest News: Options activity was heavily skewed to puts, led by 10,004 contracts of the October 16 $4 strike, so the stock’s position versus $4 into expiration matters.
Technicals: The stock traded near the bottom of its 52-week range and well below its 200-day average, with the $4 strike acting as a magnet into Friday’s expiration.
Fundamentals: IBSRELA guidance fell to $350–$370 million, and management still expects profitability in 2027.
Bull Case: Record product revenue, a $1 billion IBSRELA ambition and targets far above the price. Bear Case: A guidance cut, reimbursement friction on XPHOZAH and heavy shorting.
What to Watch:
- Position versus the $4.00 strike before Oct. 16 expiration
- Short-interest changes
- Payer and reimbursement news
Forecast: Holding above $4.00 into expiration helps the bulls and could squeeze shorts toward $4.50. A close below $3.50 opens the old $3.16 low.
Why This Matters: ARDX is the clearest example on the list of positioning, not fundamentals, deciding the next few sessions.
Stocks Under $5 to Watch Tomorrow: Sector Sentiment Snapshot and Forecast
Energy is the bright spot as oil approaches $93 and Brent holds near $100, helping SOC and KOS but leaving both exposed to any ceasefire headline. Tech hardware is weak, with LPL at a 52-week low while chip stocks sell off. Healthcare small caps run on binary events: MODD’s launch, SER’s cohort, and ARDX’s options expiration. The forecast for Tuesday is driven by bank earnings, with the Russell 2000’s 0.45% drop a reminder that small caps are lagging. Our September trending-stocks coverage tracked the same split between leaders and laggards.
At a Glance: Stocks Under $5 to Watch Tomorrow (Oct 13, 2026)
| # | Ticker | Last Close / Price | Move | Catalyst | Key Level |
|---|---|---|---|---|---|
| 1 | SOC | $3.73 | +0.3% | JPMorgan $10 target; Hondo restart | $3.59 / $4.00 |
| 2 | GOGO | $2.54 | +9.3% | No verified headline | $2.32 / $2.55 |
| 3 | LPL | ~$2.75 | New 52-wk low | Q3 report Nov. 5 | $2.75 / $2.90 |
| 4 | MODD | $2.68 | n/a | Pivot launch in five markets | $2.52 / $2.81 |
| 5 | SER | $1.94 | n/a | Parkinson’s Cohort 2 | $1.75 / $2.00 |
| 6 | QTEX | $1.77 (Oct 9) | n/a | Quantum-cryogenics pivot | $1.53 / $2.01 |
| 7 | YSG | $2.56 | n/a | Skincare +40%; Sephora deal | $2.50 / $2.98 |
| 8 | BBD | $4.33 (Oct 6) | +18.8% | Brazil rally; profit growth | $4.00 / $4.50 |
| 9 | KOS | ~$2.24 (recent) | n/a | Oil near $100 | $2.00 / $2.50 |
| 10 | ARDX | $3.90 (Aug 20) | n/a | $4 put positioning | $3.90 / $4.00 |
Follow TNN for daily stock market news and financial news today.
Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. All market investments carry inherent risks of capital loss, and small-cap, micro-cap, clinical-stage biotech, commodity-linked and other high-volatility stocks carry elevated risk. Stock prices, percentage moves, and market data cited reflect figures available at the time of publication and are subject to change. Several prices are labeled “last verified” with a date and may not reflect current trading. Support and resistance levels are analytical reference zones, not guaranteed price targets. Analyst price targets and ratings are third-party estimates and do not guarantee actual results. Always complete independent due diligence prior to executing equity trades.
About The Author
